Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Blinded, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-64457744 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Ascending Doses

Next Previous
Trial Profile

A Phase 1, Blinded, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-64457744 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Ascending Doses

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entecavir (Primary) ; JNJ 64457744 (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Janssen Research & Development

Most Recent Events

  • 07 Jun 2023 Status changed from recruiting to discontinued.
  • 11 Aug 2022 Status changed from not yet recruiting to recruiting.
  • 28 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top